Spots Global Cancer Trial Database for blastic phase

Every month we try and update this database with for blastic phase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase	NCT00383474	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Blastic Phase Recurrent Adult... Recurrent Adult... Recurrent Disea... Untreated Adult... Untreated Adult...	Bortezomib Laboratory Biom... Tipifarnib	18 Years -	National Cancer Institute (NCI)
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)	NCT01498445	Leukemia	Dasatinib Decitabine Decitabine	18 Years -	M.D. Anderson Cancer Center
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	NCT01445080	Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea...	Laboratory Biom... Pharmacological... Sorafenib Tosyl...	2 Years - 21 Years	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia	NCT01445080	Blastic Phase Childhood Acute... Childhood Chron... Childhood Solid... Chronic Myeloge... Juvenile Myelom... Philadelphia Ch... Recurrent Child... Recurrent Child... Recurrent Disea...	Laboratory Biom... Pharmacological... Sorafenib Tosyl...	2 Years - 21 Years	National Cancer Institute (NCI)
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib	NCT00036738	Adult Acute Lym... Adult B Acute L... Blastic Phase Childhood Acute... Childhood B Acu... Chronic Myeloge... Chronic Phase o... Recurrent Adult... Recurrent Child... Recurrent Disea...	Cyclosporine Dasatinib Fludarabine Pho... Imatinib Mesyla... Mycophenolate M... Nilotinib Nonmyeloablativ... Peripheral Bloo... Therapeutic All... Total-Body Irra...	- 70 Years	Fred Hutchinson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: